// App-Quantinova.ai

SAT0155 (2017) : ADALIMUMAB IN COMBINATION WITH NON-METHOTREXATE CONVENTIONAL SYNTHETIC DISEASE MODIFYING RHEUMATIC DRUGS IN A CLINICAL TRIAL SETTING

Researchers

Presenter

  • E.C. Keystone

Principal Investigators

  • J. Suboticki

  • J. Griffith

  • Y. Zhang

  • J.M. Kremer

Medical Centers

  • St Michael's Hospital, University of Toronto, Toronto, ON, Canada

  • AbbVie, Inc., North Chicago, IL

  • Albany School of Medicine, Albany, United States

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Methotrexate

  • HWA-486

  • Adalimumab

  • Hydroxyzine

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved